| ID | Sequence | Length | GC content |
|---|---|---|---|
| CUUCCCUGCCCGGGUCUCCUCGCUGUCGCCGCCGCUGCCACACCAUGGC… | 1854 nt | 0.4601 | |
| AUUCAGGAGGAGUAACUGGAAGCCAUAACCAUGAACUUCCAUAUCUGUC… | 1934 nt | 0.4421 | |
| CUUCCCUGCCCGGGUCUCCUCGCUGUCGCCGCCGCUGCCACACCAUGGC… | 1803 nt | 0.4615 |
This gene is a member of the 3-hydroxyacyl-CoA dehydrogenase gene family. The encoded protein functions in the mitochondrial matrix to catalyze the oxidation of straight-chain 3-hydroxyacyl-CoAs as part of the beta-oxidation pathway. Its enzymatic activity is highest with medium-chain-length fatty acids. Mutations in this gene cause one form of familial hyperinsulinemic hypoglycemia. The human genome contains a related pseudogene of this gene on chromosome 15. [provided by RefSeq, May 2010]
A study in humans demonstrated that the HADH gene, involved in lipid metabolism, was downregulated in the adipose tissue of heavier co-twins within BMI-discordant monozygotic twin pairs, indicating its role in the mitochondrial dysfunction associated with acquired obesity [van der Kolk et al. DOI:10.1016/j.xcrm.2021.100226]. A study in rats demonstrated that the HADH (Hadhb) was identified as a potential regulator of methamphetamine reward and addiction via transcriptome profiling of whisker follicles, showing a down-down regulated expression pattern (0.69 at MASA, 0.48 at WD) and a betweenness centrality score of 0.0147, and it was previously reported as an addiction-related gene [Song et al. DOI:10.1038/s41598-018-29772-1].